ZDNET的关键外卖
- 胰岛素抗药性血压趋势来到Fitbit空气和Fitbit边缘。
- 这些新功能仅供Google健康保费用户使用。
- 新闻显示Google在发展连续的葡萄糖监测器方面有更大的健康任务。
Google刚刚在Fitbit Air和Edge上增加了胰岛素抗药性和血压趋势，将这些设备超越了基本健身监测和睡眠跟踪，并进入了更深层次的健康洞察力。 这些新功能是Google为像素观察和Fitbit提供的一套主动安全工具的一部分。
还有：AI健康教练订阅是骗局吗？测试Fitbit一个月后
专供Google健康保费用户使用，每年100美元订阅，允许用户使用Google的AI健康导师
更多来自 ZDNET
其算法分析心率、活动水平、睡眠和其他衡量标准，Fitbit也会在不戴手铐的情况下追踪你的血压模式，合格Fitbit Air和Fitbit Edge用户已经磨损了5天或更长时间的装置，可以在应用的保健标签中看到这种见解。
与血压趋势类似，胰岛素抗药性特征使用Fitbit传感器来监测代谢健康的变化。 胰岛素抗药性是2型糖尿病的前兆，有可能让使用者以较少侵入性的方式洞察其胰岛素水平的变化，但比直接诊断更能指向总体趋势。
与连续的葡萄糖监测器不同，它穿透皮肤并利用血液来收集代谢数据，胰岛素抗药性特征是通过它的多式联运模型来评估生物测定和代谢模式的。 Google根据它在《自然》的论文，根据其他可穿戴物收集的数据以及汇编的人口数据，对其胰岛素抗药性模型进行了培训。
还有：我测试了Google的Fitbit边缘
一旦该特性检测到高水平的胰岛素抗药性模式，便通知用户采取额外行动。 Fitbit用户甚至可以将其Abbott CGM与Google健康应用连接，用于额外的葡萄糖监测。 Google通过向更多的设备提供这些健康卫士功能，而不仅仅是它的旗舰像素观察器，让更多的用户——具体来说是拥有100美元和180美元Fitbit Air或Edge的预算意识用户——能够跟踪和保持在一些常见和严重的健康状况之前。
虽然胰岛素抗药性特征离非入侵性CGM的能力还差得很远，但Google开发的跟踪胰岛素活动生物特征反应的多式联运模型表明，该公司正接近于非入侵性现实。
非侵入性葡萄糖监测就像可穿戴技术的可折叠手机。 这个产品想法已经持续了好几年，每个技术公司都在竞相部署自己的技术，甚至史蒂夫·乔布斯也梦到人们可以使用的Apple葡萄糖监测器——不需要手指刺。 有传言称Apple也为此工作多年。
但是，Google可能比Apple在这架上先走几步。 它向新Fitbit设备部署胰岛素抗药性趋势，是它向使用算法AI而不是针头和血液的CGM推进的一种方式。
本文由 AI图鉴自动抓取并翻译，版权归原作者所有；如需查看原文请点下方链接。
ZDNET’s key takeaways
- Insulin resistance and blood pressure trends are coming to the Fitbit Air and Fitbit Edge.
- These new features are available for Google Health Premium users only.
- The news points at Google’s greater health mission in developing a continuous glucose monitor.
Google just added insulin resistance and blood pressure trends to the Fitbit Air and Edge, taking these devices beyond basic fitness monitoring and sleep tracking and into deeper health insights. The new features are part of Google’s “Health Guardian” suite of proactive safety tools for the Pixel Watch and Fitbit.
Also: Are AI health coach subscriptions a scam? My verdict after testing Fitbit’s for a month
They’re available solely for Google Health Premium users, a $100 annual subscription that grants users access to Google’s AI health coach, advanced sleep tracking, and a more expansive selection of health-tracking features.
More from ZDNET
While it doesn’t measure your insulin or glucose outright, its algorithm analyzes heart rate, activity level, sleep, and other metrics to show changes in metabolic health. The Fitbit will also track your blood pressure patterns without a cuff, monitor your pulse while you’re asleep or awake, and, at the end of the month, provide you with insights. Eligible Fitbit Air and Fitbit Edge users who have worn their device for five days or more will see this insight in the Health tab of the app.
Similar to blood pressure trends, the insulin resistance feature uses Fitbit sensors to monitor shifts in metabolic health. Insulin resistance is a precursor to type 2 diabetes, potentially giving users insight into changes in their insulin levels in a less invasive way, but pointing more toward overall trends than a direct diagnosis.
Unlike a continuous glucose monitor, which penetrates the skin and uses blood to gather metabolic data, the insulin resistance feature was built to assess biometric and metabolic patterns through its multimodal model. Google trained its insulin resistance model on data gathered by other wearables as well as compiled demographic data, according to its paper in Nature.
Also: I tested Google’s Fitbit Edge – its standout feature also left me wanting more
Once the feature detects elevated insulin resistance patterns, it notifies the user to take additional action. Fitbit users can even connect their Abbott CGM to the Google Health app for additional glucose monitoring. By offering these Health Guardian features to more devices than just its flagship Pixel Watches, Google is giving more users — specifically budget-conscious users who own a $100 and $180 Fitbit Air or Edge — the ability to track and stay ahead of some common and serious health conditions.
While the insulin resistance feature is nowhere near the capabilities of a non-invasive CGM, Google’s development of a multimodal model for tracking biometric responses to insulin activity suggests the company is getting closer to that non-invasive reality.
Non-invasive glucose monitoring is like the foldable phone of wearable technology. It’s a product idea that’s been around for years now, and every tech company is racing to deploy its own, with varying degrees of success and adoption. Even Steve Jobs had dreams of an Apple glucose monitor that people could use — no finger prick necessary. Rumors suggest that Apple has also been working on this for years now.
But Google might be a few steps ahead of Apple on this one. Its deployment of insulin resistance trends to new Fitbit devices is one way it is advancing toward a CGM that uses algorithmic AI instead of needles and blood.
Auto-fetched and translated by AI Atlas. All rights belong to the original author.